1 Introduction Prolactinomas (PRLomas) are the most common type of functional pituitary adenomas (PAs) ( PRL-secreting PAs are an exception among other PAs, as pharmacotherapy is the first line of treatment ( 2 Epidemiology PRLomas are the most common type of PAs and account for about 53% (39.9-66.2%) of them, with a marked female predominance ( In males, PRLomas are notably larger than those in females and, at the time of the diagnosis, are likely to be macroadenomas with high serum PRL concentration ( PRLomas are also the second most common type of pituitary carcinomas (PC), representing up to one-third of them and approximately 0.04% of all pituitary tumors ( Most often, PRL-secreting PAs occur sporadically, but up to 5% of cases develop as a component of the familial genetic syndrome, such as multiple endocrine neoplasia type 1 (MEN-1), MEN-4, Carney complex, familial isolated pituitary adenomas (FIPA) and familial pheochromocytoma/paraganglioma/pituitary adenoma (3PA) syndrome ( 3 Pathogenesis As mentioned above, PRLomas in men, in comparison to women, are usually larger, more invasive and show higher PRL concentration at the time of the diagnosis ( Histological, molecular and clinical factors differences between lactotroph tumors in women and men are summarized in Figure 1
Emerging data implies that the amino acid sequence in GHK-Cu might possess antioxidative characteristics
As for in vivo validation, with/without DEHP-treated BRCA cell lines could be implanted into mice to assess their tumorigenicity
Peptide bioregulators are not approved by the FDA or comparable Western regulators for any use
Psychometric evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia and control subjects
The future of medicine is here, and it focuses on supporting cellular communication and tissue repair rather than masking visible changes
